Matrix Capital Management Company, LP
- SEC CIK
- 0001410830
- Latest filing
- Aug 13, 2026
The latest 13F from Matrix Capital Management Company, LP covers Q2 2026 (filed Aug 13, 2026) and reports no long positions. Livermore has 22 filings on Form 13F from this institution, going back to Q1 2021.
What changed in Q2 2026
Share counts compared with Q1 2026: how many positions were new, added to, reduced or sold out, and the biggest buys and sells. Dollar amounts are estimated at the quarter-end prices implied by the filing.
- New
- 0
- Added
- 0
- Reduced
- 0
- Sold out
- 1
- Est. −$46.3M
Top 5 holdings
Share of this quarter's portfolio value
This filing reports no long positions.
Biggest buys
New and added positions, by estimated amount bought
None this quarter.
Largest weight increases
New and added positions, by percentage points of the portfolio gained
None this quarter.
Metrics
13F metrics for Q2 2026, computed only from the numbers in the filings. Definitions below.
- Portfolio value
- $0
- −$46.3M (−100.0%) vs. prior quarter
- Positions
- 0
- −1 vs. prior quarter
- Top 10 concentration
- –
- Top 10 as share of value
- Turnover
- 0.0%
- Q2 2026, one quarter
- Average holding period
- –
- Weighted by value
How these are calculated
- Portfolio value: the market value of all long positions in the 13F, as reported at quarter end, excluding options.
- Top 10 concentration: the combined value of the 10 largest positions as a share of portfolio value.
- Turnover: the smaller of this quarter's estimated purchases and estimated sales, divided by the average of this and last quarter's portfolio value. Estimates multiply the change in shares by the quarter-end price implied by the filing (market value divided by shares); new positions use this quarter's value and sold-out positions last quarter's. Only positions reported in shares count, and it is not calculated when the previous quarter was not filed.
- Average holding period: how many consecutive quarters each current position has been held (including this one; a quarter without the position or without a filing starts the count over), weighted by this quarter's value. Counting starts with the first 13F in Livermore (Q1 2021), so positions held before then are understated.
13F filings by quarter
22 quarters, going back to Q1 2021. Bars show each quarter's 13F portfolio value; quarters without a filing are left blank.
Peak $13.1B (Q2 2024)
| Quarter | Filed | Positions | Value | Top 3 holdings | Changes | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 13, 2026 | 0 | $0 | – | vs. Q1 2026 | SEC |
| Q1 2026 | May 14, 2026 | 1 | $46.3M | AURA | vs. Q4 2025 | SEC |
| Q4 2025 | Feb 13, 2026 | 2 | $57.6M | AURAMAZE | vs. Q3 2025 | SEC |
| Q3 2025 | Nov 13, 2025 | 3 | $106.7M | MAZEAURAZNTL | vs. Q2 2025 | SEC |
| Q2 2025 | Aug 14, 2025 | 4 | $222.8M | GFSAURAMAZE | vs. Q1 2025 | SEC |
| Q1 2025 | May 14, 2025 | 4 | $347.2M | GFSAURAMAZE | vs. Q4 2024 | SEC |
| Q4 2024 | Feb 13, 2025 | 5 | $2.15B | ALTRGFSPRM | vs. Q3 2024 | SEC |
| Q3 2024 | Nov 14, 2024 | 7 | $2.09B | ALTRGFSPRM | vs. Q2 2024 | SEC |
| Q2 2024 | Aug 14, 2024 | 23 | $13.1B | NVDAQCOMTDG | vs. Q1 2024 | SEC |
| Q1 2024 | May 14, 2024 | 23 | $10.8B | NVDATDGQCOM | vs. Q4 2023 | SEC |
| Q4 2023 | Feb 13, 2024 | 19 | $9.72B | NVDAAMATAMZN | vs. Q3 2023 | SEC |
| Q3 2023 | Nov 14, 2023 | 19 | $8.34B | NVDAGFSAMAT | vs. Q2 2023 | SEC |
| Q2 2023 | Aug 14, 2023 | 19 | $8.61B | NVDAGFSAMAT | vs. Q1 2023 | SEC |
| Q1 2023 | May 15, 2023 | 17 | $7.36B | NVDAGFSTDG | vs. Q4 2022 | SEC |
| Q4 2022 | Feb 13, 2023 | 17 | $5.24B | GFSNVDATDG | vs. Q3 2022 | SEC |
| Q3 2022 | Nov 14, 2022 | 26 | $5.23B | GFSTDGCRWD | vs. Q2 2022 | SEC |
| Q2 2022 | Aug 15, 2022 | 20 | $4.41B | TDGGFSCRWD | vs. Q1 2022 | SEC |
| Q1 2022 | May 16, 2022 | 25 | $8.33B | DISNFLXTDG | vs. Q4 2021 | SEC |
| Q4 2021 | Feb 15, 2022 | 22 | $8.98B | NFLXTDGCRM | vs. Q3 2021 | SEC |
| Q3 2021 | Nov 15, 2021 | 23 | $8.79B | NFLXCRWDCRM | vs. Q2 2021 | SEC |
| Q2 2021 | Aug 16, 2021 | 23 | $9.15B | NFLXCRWDDIS | vs. Q1 2021 | SEC |
| Q1 2021 | May 17, 2021 | 30 | $8.66B | NFLXDISTDG | – | SEC |
13D and 13G filings
Companies where Matrix Capital Management Company, LP reports owning 5% or more on Schedule 13D or 13G, and its latest filings.
Current stakes of 5% or more
Matrix Capital Management Company, LP does not currently report owning 5% or more of any company.
Latest filings
39 filings on file made by Matrix Capital Management Company, LP or listing it as a reporting person; the latest 20 are shown.
| Company | Filed (ET) | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| AURAAura Biosciences, Inc. | May 11, 20264:15 PM ET | 13D/A | 0.00%0 shares | −11.17 ppfrom 11.17%Below 5% | May 7, 2026 | SEC |
| ZNTLZentalis Pharmaceuticals, Inc. | Jan 2, 20264:10 PM ET | 13D/A | 0.00%0 shares | −9.98 ppfrom 9.98%Below 5% | Dec 30, 2025 | SEC |
| ZNTLZentalis Pharmaceuticals, Inc. | Dec 15, 20255:16 PM ET | 13D/A | 9.98%6.46M shares | – | Dec 15, 2025 | SEC |
| MAZEMaze Therapeutics, Inc. | Nov 13, 20254:10 PM ET | 13G/A | 3.50%1.65M shares | −2.20 ppfrom 5.70%Below 5% | Sep 30, 2025 | SEC |
| AURAAura Biosciences, Inc. | May 19, 20254:35 PM ET | 13D/A | 11.17%6.92M shares | – | May 16, 2025 | SEC |
| MAZEMaze Therapeutics, Inc. | May 14, 20254:10 PM ET | 13G | 5.70%2.49M shares | New | Mar 31, 2025 | SEC |
| ALTRAltair Engineering Inc. | Apr 7, 20254:15 PM ET | 13G/A | 0.00%0 shares | –Below 5% | Mar 31, 2025 | SEC |
| PRMPerimeter Solutions, Inc. | Feb 12, 20255:00 PM ET | 13G/A | 4.48%6.55M shares | –Below 5% | Dec 31, 2024 | SEC |
| ADAPYAdaptimmune Therapeutics PLC | Jan 8, 202510:30 AM ET | 13G/A | 0.00%0 shares | −8.80 ppfrom 8.80%Below 5% | Dec 31, 2024 | SEC |
| ADAPYAdaptimmune Therapeutics PLC | Dec 5, 20245:17 PM ET | 13G/A | 8.80%135.0M shares | – | Nov 30, 2024 | SEC |
| ALTRAltair Engineering Inc. | Nov 13, 2024 | 13G/AOld format | – | – | – | SEC |
| ADAPYAdaptimmune Therapeutics PLC | Nov 13, 2024 | 13G/AOld format | – | – | – | SEC |
| ADPTAdaptive Biotechnologies Corp | Nov 13, 2024 | 13G/AOld format | – | – | – | SEC |
| ALTRAltair Engineering Inc. | Feb 13, 2024 | 13G/AOld format | – | – | – | SEC |
| AURAAura Biosciences, Inc. | Nov 9, 2023 | 13D/AOld format | – | – | – | SEC |
| ADAPYAdaptimmune Therapeutics PLC | Jul 10, 2023 | 13G/AOld format | – | – | – | SEC |
| ZNTLZentalis Pharmaceuticals, Inc. | Jun 20, 2023 | 13D/AOld format | – | – | – | SEC |
| NEWRNew Relic, Inc. | Feb 13, 2023 | 13G/AOld format | – | – | – | SEC |
| FORGForgeRock, Inc. | Feb 13, 2023 | 13G/AOld format | – | – | – | SEC |
| ALTRAltair Engineering Inc. | Feb 13, 2023 | 13G/AOld format | – | – | – | SEC |